Moomoo AI 已提取核心信息
On February 5, 2024, Exicure, Inc., a biotechnology company known for developing nucleic acid therapies, announced a patent license agreement with Bluejay Therapeutics, Inc., a private biopharmaceutical company. The agreement grants Bluejay an exclusive license to use Exicure's patents for developing cavrotolimod as a potential treatment for hepatitis. Bluejay made an initial payment to Exicure and will also pay royalties on future net sales of any licensed technology. Exicure retains responsibility for patent maintenance and prosecution. CEO Paul Kang highlighted the partnership's alignment with Exicure's strategic shift towards maximizing shareholder value following a restructuring and suspension of clinical activities. The company is exploring strategic alternatives for its biotechnology assets.
On February 5, 2024, Exicure, Inc., a biotechnology company known for developing nucleic acid therapies, announced a patent license agreement with Bluejay Therapeutics, Inc., a private biopharmaceutical company. The agreement grants Bluejay an exclusive license to use Exicure's patents for developing cavrotolimod as a potential treatment for hepatitis. Bluejay made an initial payment to Exicure and will also pay royalties on future net sales of any licensed technology. Exicure retains responsibility for patent maintenance and prosecution. CEO Paul Kang highlighted the partnership's alignment with Exicure's strategic shift towards maximizing shareholder value following a restructuring and suspension of clinical activities. The company is exploring strategic alternatives for its biotechnology assets.
2024年2月5日，以开发核酸疗法而闻名的生物技术公司Exicure, Inc. 宣布与私营生物制药公司Bluejay Therapeutics, Inc. 签订专利许可协议。该协议授予Bluejay独家许可，允许其使用Exicure的专利开发卡夫罗莫德作为肝炎的潜在治疗方法。Bluejay向Exicure支付了首笔款项，还将为任何许可技术的未来净销售额支付特许权使用费。Exicure保留专利维护和起诉的责任。首席执行官保罗·康强调，该合作伙伴关系与Exicure在重组和暂停临床活动后向实现股东价值最大化的战略转变一致。该公司正在为其生物技术资产探索战略替代方案。
2024年2月5日，以开发核酸疗法而闻名的生物技术公司Exicure, Inc. 宣布与私营生物制药公司Bluejay Therapeutics, Inc. 签订专利许可协议。该协议授予Bluejay独家许可，允许其使用Exicure的专利开发卡夫罗莫德作为肝炎的潜在治疗方法。Bluejay向Exicure支付了首笔款项，还将为任何许可技术的未来净销售额支付特许权使用费。Exicure保留专利维护和起诉的责任。首席执行官保罗·康强调，该合作伙伴关系与Exicure在重组和暂停临床活动后向实现股东价值最大化的战略转变一致。该公司正在为其生物技术资产探索战略替代方案。
有用
没用